Literature DB >> 7273650

The management of generalised grade 2 non-Hodgkin's lymphomas (Report no 18).

K W Pettingale.   

Abstract

This report describes a comparison of combination chemotherapy (CHOP) with total body irradiation (TBI) in the management of Stages III and IV Grade 2 non-Hodgkin's lymphoma. This prospective randomised study was carried out by the BNLI between 1974 and 1978. One hundred and fourteen previously untreated patients were accepted: 66 received CHOP and 48 TBI. Complete remission was obtained in 39% of patients treated with CHOP and 23% with TBI. This difference is not significant. However, when comparison is stratified for Stage III disease the survival of the CHOP-treated group is statistically significant (chi(2) = 4.125: 0.05 greater than P greater than 0.025). This difference in favour of CHOP is most marked in patients with poorly differentiated histology. Only 46% of patients receiving CHOP remain alive at the time of this report. There is urgent need for more effective treatment in the management of this type of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273650     DOI: 10.1016/s0009-9260(81)80186-9

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.

Authors:  G Sangster; W N Patton; R I Harris; R J Grieve; M J Leyland
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.

Authors:  M De Lena; E Maiello; V Lorusso; M Brandi; P Calabrese; S Romito; A Mazzei; F Marzullo
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).

Authors:  J A Child; D L Barnard; S C Cartwright; I Lauder; A V Simmons; J Stone; J Thorogood
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.